APG-2449 in Patients With Advanced Solid Tumors

• Status: Recruiting
• Trial end date: 2023-05-01
• Target enrollment: 0
• Participant gender: All

Summary

APG-2449 is a novel, orally active, multi-targeted tyrosine kinase inhibitor, which inhibits FAK, ALK, and ROS1 with nanomolar potencies. In preclinical studies, APG-2449 demonstrated potent antiproliferative activity in various cancer cell lines as a single agent. In combination treatment, APG-2449 enhanced anti-proliferative activities of several chemotherapeutic and targeted agents. It is indicated that APG-2449 may have a broad therapeutic potential for the treatment of human cancer as a single agent and in combination with other classes of anticancer drugs. APG-2449 is intended for the treatment of patients with advanced solid tumors. Upon completion of the Phase 1 dose escalation study to establish the maximum tolerated dose (MTD), dose-limiting toxicities (DLTs), and/or recommended phase 2 dose (RP2D), several phase Ib/II studies will be implemented accordingly.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Ascentage Pharma Group Inc.
• Collaborator: Suzhou Yasheng Pharmaceutical Co., Ltd.

Criteria

Inclusion Criteria:

1. Dose exploration stage: non-small cell lung cancer diagnosed by histology and/or cytology and positive for ALK/ROS1 gene fusion (molecular diagnosis confirmed by the investigator) and malignant pleural mesothelioma, esophageal cancer and ovarian cancer. Kind of patients with advanced tumors.

Expansion stage: cohort one, patients with non-small cell lung cancer who have progressed or intolerable after the second-generation ALK/ROS1 TKI (Alectinib or Ceritinib or Brigatinib or Ensartinib) treatment; cohort two, ALK/ROS1 fusion gene positive without TKI treatment Patients with non-small cell lung cancer. The molecular diagnosis results of the above patients can be confirmed by the investigator.

2. ECOG Performance Status ≤ 1.

3. Expectation of life ≥ 3 months.

4. According to RECIST version 1.1, there is at least 1 measurable lesion.

5. Adequate hematologic and bone marrow functions.

6. Adequate renal and liver function.

7. Normal cardiac function.

8. Brain metastases with clinically controlled neurologic symptoms.

9. Serum pregnancy test results of women of childbearing age were negative within 7 days before taking the first dose of study drug.

10. Men, women of childbearing age (postmenopausal women must have been menopausal for at least 12 months before they can be considered infertile) and their partners voluntarily take the study drug for at least 30 days after signing the informed consent form and taking the study drug as deemed effective by the investigator Contraceptive measures

11. Ability to understand and willingness to sign a written informed consent form

12. Subjects must be willing and able to complete the research procedures and follow-up inspections.

Exclusion Criteria:

1. Receiving concurrent anti-cancer therapy (chemotherapy, radiotherapy, immunotherapy, biologic therapy); or any investigational therapy within 28 days prior to the first dose of study drug.

2. Receiving TKI therapy within 8 days prior to the first dose of study drug.

3. Continuance of toxicities due to prior therapy that do not recover (CTCAE V5.0 Grade> 1).

4. Has difficulty in swallowing, absorbing barrier, or other diseases blocking APG-2449' taken.

5. Obvious cardiovascular disease history.

6. Failure to recover adequately, as judged by the investigator, from prior surgical procedures. Patients who have had major surgery within 28 days from study entry, and patients who have had minor surgery within 14 days of study entry.

7. Active symptomatic fungal, bacterial and/or viral infection including, but not limited to, active human immunodeficiency virus (HIV) or viral hepatitis (B or C).

8. Known allergies to study drug ingredients or their analogs.

9. Female subjects who are pregnant or breastfeeding, or expecting to become pregnant during the study period.

10. According to the judgment of the investigator or sponsor, any symptoms or disease of the subject may endanger its safety or interfere with the safety assessment of the study drug.

11. Subjects who have used CYP3A4, CYP2C9, or CYP2C19 moderately potent inhibitors or moderately potent inducers 1 week before receiving the study drug for the first time.

12. Subjects who used CYP3A4 substrates and narrow treatment window 1 week before the first study drug.